Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00797004
Other study ID # 35031-B
Secondary ID
Status Completed
Phase N/A
First received November 21, 2008
Last updated June 27, 2012
Start date November 2008
Est. completion date September 2010

Study information

Verified date June 2012
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this research is to improve understanding of the molecular and functional properties of the human olfactory system.

The specific aims are:

- to determine the location of AC3 and Golf proteins in the human olfactory epithelium from freshly harvested nasal/sinus tissue of surgical patients

- to perform objective functional studies on fresh human nasal/sinus tissue using an electro-olfactogram (EOG) whic measures the electrical activity of olfactory sensory neurons in fresh biopsied tissue in response to odor or pheromone stimulation. An organotypic culture system for human tissue has been established to optimize the electrical signal acquisition.

- to correlate the AC3 and Golf expression profiles with pre-operative testing of human olfactory function

- to correlate the EOG findings with pre-operative testing of human olfactory function.

- to systematically evaluate the role of individual intranasal agents on olfaction to further optimize the electrical signal acquisition from olfactory tissue.


Description:

This is a prospective cohort study. Subjects will be recruited from the group of patients at the University of Washington Otolaryngology-Head and Neck Surgery Clinic who will undergo endoscopic sinus surgery for chronic sinusitis and other disorders of the nasal cavity and sinuses.

Subjects will sign consent and complete a subjective smell test (UPSIT--University of Pennsylvania Smell Identification Test), and the SNOT-20 (Sinonasal Outcome Test-20)

During their surgery, subjects will have two to four pieces of normally discarded tissue preserved for the study. Subjects will also have two to four pieces of healthy tissue removed (total size approximately that of a pencil eraser tip)depending on the type of surgery involved. The following procedures will be performed on these tissues:

- immunocytochemistry utilizing antibodies to AC3 and Golf to determine the patterns and levels of expression of these proteins

- two odorants, isoamyl acetate and citralva, to elicit odorant-induced activity from the human olfactory sensory neurons. The tissue will also be subjected to two putative human pheromones: 4,16-androstadiene-3-ol and 1,3,5(10),16-estrateraen-3-ol.

- application of six commonly used intranasal agents: 0.9% saline, 1:1000,000 epinephrine, 0.05% oxymetazoline, 1% lidocaine, Zicam (0.12% zinc gluconate) and Nasocort AQ (triamcinolone acetate).


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- over 18 yrs. of age, scheduled for: a.) endoscopic sinus surgery for chronic sinusitis, b.) endoscopic transnasal approach to the pituitary for pituitary tumor removal, c.) endoscopic inferior turbinectomy for nasal congestion d.)endoscopic repair of cerebrospinal fluid leaks

Exclusion Criteria:

- unable to give informed consent or complete questionnaires due to language, cognitive impairment or sever medical conditions.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States University of Washington Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Greg Davis

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lim JH, Davis GE, Rue TC, Storm DR. Human sinonasal explant system for testing cytotoxicity of intranasal agents. Int Forum Allergy Rhinol. 2012 Jan-Feb;2(1):63-8. doi: 10.1002/alr.20110. Epub 2011 Dec 13. — View Citation

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02636790 - Early Versus Late Surgical Wait Times Early Phase 1
Completed NCT02712502 - Levofloxacin in Bacterial Rhinosinussitis N/A
Completed NCT00986830 - Healthcare Utilization and Outcomes of FinESS Treatment in the Office N/A
Completed NCT00534079 - Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Phase 3
Completed NCT05442606 - Physiotherapy Protocol in Treating Chronic Rhinosinusitis N/A
Completed NCT01955980 - Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis Phase 1/Phase 2
Completed NCT04123405 - Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis Phase 3
Recruiting NCT05494346 - Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction N/A
Not yet recruiting NCT05836935 - Role of Imaging in Complications of Sinusitis N/A
Withdrawn NCT02097576 - Manuka Honey Nasal Rinse Study N/A
Completed NCT01132781 - Theophylline in Rhinitis Phase 2
Recruiting NCT00948519 - Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents N/A
Completed NCT00554190 - Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel Phase 4
Recruiting NCT03729258 - Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. Phase 3
Withdrawn NCT03729310 - Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis Early Phase 1
Recruiting NCT01296919 - The Clinical Significance of the Uncinate Process Histopathology in Chronic Rhinosinusitis N/A
Completed NCT01086839 - Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis N/A
Completed NCT00849953 - FinESS Registry Study N/A
Withdrawn NCT00669799 - Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study N/A
Completed NCT03229551 - Xylitol for Chronic Sinusitis Phase 2/Phase 3